The current standard of care for the frontline treatment of peripheral T-cell lymphomas
(PTCL) is induction chemotherapy followed by autologous stem cell transplantation (ASCT).
However, many patients are unable to get to ASCT or relapse after ASCT, with a poor
prognosis. Recently, a novel ASCT conditioning regimen of gemcitabine, busulfan and melphalan
(Gem/Bu/Mel) has been reported to lead to favorable outcomes in this disease. We therefore
designed a frontline regimen of CHOEP induction followed by Gem/Bu/Mel ASCT, and report the
results of a phase 2 study of this regimen in patients with PTCL.